Mike’s note: Lately it’s been hard to ignore the outstanding performance of the tech sector – even in the face of a global pandemic and recession.

But as Jeff pointed out yesterday, not all tech stocks should be approached the same way. Even though a select few appear to be dominating the sector currently, a little research can unearth opportunities with the potential to eclipse the “hottest” names in the industry.

Our colleague and tech expert Jeff Brown knows exactly where to find those opportunities. Even better, he thinks we’re about to enter a “golden age” of a tech sector that’s gone mostly overlooked, until now – thanks in part to a global pandemic in need of immediate vaccinations and treatments.

Read on to see why Jeff Brown believes this sector will help to cure diseases at an unprecedented speed, and if you haven’t already, be sure to sign up for Jeff’s exclusive upcoming event where he’ll show you how to potentially profit off of this exploding sector…


By Jeff Brown, editor, Early Stage Trader

There’s no going “back to normal.”

My longtime readers already know this, but COVID-19 has changed our world permanently.

We can easily identify the obvious changes. There are more remote working options. Online grocery delivery is being quickly adopted. And, going forward, industries will have to rethink every major conference and public gathering.

But there are also less obvious changes taking place…

Breakthroughs in one technology sector that were five to ten years away are now happening on a monthly or weekly basis.

Which technology sector am I referring to? Biotechnology.

We’re at the start of a multiyear bull market in biotech. The pandemic has opened the doors for radically new approaches to vaccines and therapies, many of which were not taken seriously before.

It’s going to help us cure diseases at a pace previously unseen.

And for investors, it presents a once-in-a-generation opportunity to create enormous wealth.

The Rise of Biotech

When we picture biotechnology, I imagine 99% of us think of scientists in white lab coats fiddling with test tubes and peering under microscopes.

But the story is far more interesting. As I like to tell readers, biotech is much more “tech” than “bio” these days.

Today, the biotechnology industry is using big data, machine learning, and artificial intelligence to make breakthroughs that – even just a few years ago – would have seemed impossible.

Consider just one example…

Back in March, an early stage biotech firm AbCellera did something that many people thought was impossible.

AbCellera received a blood sample from a patient who had recovered from COVID-19. The company used artificial intelligence (AI) to screen more than five million immune cells in that sample. And it identified about 500 antibodies that helped the patient fight off the virus.

Identifying these antibodies could be the key to treating COVID-19. AbCellera used this as a starting point to create an antibody therapy to potentially cure COVID-19.

Historically, this process would have taken years to accomplish. So how long did it take AbCellera? Just 11 days. Beyond incredible.

And the industry took notice…

Pharmaceutical giant Eli Lilly rushed to partner with AbCellera. They worked on a treatment using these antibodies.

And in June, AbCellera sent its COVID-19 antibody therapy to clinical trials. It was the first company to do so.

If these clinical trials go well, the company could receive emergency use authorization (EUA) from the Food and Drug Administration (FDA). That will allow AbCellera to offer its therapy to the public in time for autumn.

That’s important because we will likely see a second wave of COVID-19 cases when the weather gets cool and dry again.

Think about this for a minute. An early stage biotech took blood samples and identified COVID-19 antibodies. It then developed a therapy and launched clinical trials. And it did all this in the span of four months. Until just recently, this process would have taken several years.

Make no mistake, this is revolutionary work.

In all my years as an analyst, I’ve never seen this type of speed from the biotech industry. And it’s thanks in large part to COVID-19. The virus has lit a fire under this overlooked industry.

But investors are now starting to notice…

Money Is Flooding Into Biotech

Suddenly, the world has woken up to the potential of biotechnology.

Every venture capitalist and private equity house has realized how powerful these technologies are and how quickly biotech can move. We’re going to see an acceleration in biotech investment, early stage companies, and IPOs (initial public offerings) as a result.

In fact, we’re already seeing that.

51% of all traditional IPOs this year have been biotechnology companies. And collectively, these companies have raised nearly $5 billion for drug development.

The 2020s will be the decade of biotech. This will be the first decade in which biotechnology companies truly harness the power of Moore’s Law and demonstrate exponential growth.

For us as investors, we need to be paying attention.

We can think of it this way…

In early 2017, cryptocurrencies were mostly unknown, niche asset. But then the cryptocurrency space went on an unprecedented bull run before its painful correction in 2018. Bitcoin alone rose over 2,000% in 2017.

And I believe investors’ awareness and engagement in early stage biotech companies will rival that of the last crypto bull market.

But unlike cryptocurrencies – many of which were backed by nothing – early stage biotech is supported by very real, world-changing technology. The returns we will see from quality biotech companies will create lasting, generational wealth.

We are at the very beginning of a years-long biotech bull market. Breakthroughs will continue to happen. Diseases – previously thought untreatable – will be cured. And yes, fortunes will be made.

We are entering a golden age of biotechnology. And it’s happening right now.

And I believe I’ve found the perfect way to profit from this explosion in biotechnology.

99% of investors are distracted by the “big name” biotech stocks they see on CNBC. But hardly anybody is paying attention to a small, niche sector of the biotech market. Here, triple-digit gains are possible in days or even hours.

Thanks to the federal government, these stocks have a preset “timer” attached to their share price. And once that timer hits zero, the stock can skyrocket.

I call these investments “timed stocks.” And thanks to two seemingly unrelated forces, “timed stocks” are actually accelerating.

More of these stocks are coming onto the market. The gains are larger, and they are happening more frequently.

The investment potential here is unlike anything I’ve seen.

I invite you to learn more about “timed stocks” by joining me Wednesday, July 15 at 8 p.m. ET. On that date, I’m hosting Timed Stocks Accelerated – a special investing seminar where I’ll reveal everything I’ve learned about these stocks.

I’ll see you there.

Regards,

Jeff Brown
Editor, Early Stage Trader

In Case You Missed It…

Investigation uncovers up to 100,000 companies using private “6G” network

Angel investor Jeff Brown just uncovered a shocking tech story.

As many as 100,000 of the world’s largest companies are using a private “6G” network – even as it remains unavailable to the general public.

The list includes:

Find out who the company behind 6G is – and why they collected $10 billion in revenue last quarter alone.

image